Condition-specific health context in a specific context is closer to a research marker, so it should be read separately from a directly felt benefit.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Paper IDs and full lists are private. Only study types and summaries are shown.
A best practice workflow for laboratory scientists to evaluate discrepant immunoassay results is proposed, comprising: serial dilution; retesting after biotin clearance and/or repeat testing on an alternate platform; and confirmation of the presence of biotin
A smaller promiscuous biotin ligase for proximity biotinylation called BioID2 enables more-selective targeting of fusion proteins, requires less biotin supplementation, exhibits enhanced labeling of proximate proteins, and demonstrates the use of a flexible li
In a double-blind, placebo-controlled study, MD1003 achieves sustained reversal of MS-related disability in a subset of patients with progressive MS and is well tolerated.
Four-week probiotic plus biotin supplementation, in inpatient individuals with a major depressive disorder diagnosis, showed an overall beneficial effect of clinical treatment, however, probiotic intervention compared to placebo only differed in microbial dive
This study showed that MD 1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests,
The information contained in these tables was designed as educational tools to aid laboratory professionals and clinicians in troubleshooting cardiac biomarker analytical results that are discordant with the clinical situation.